Louisiana's drug reclassification delays hemorrhage treatment, raising risks for pregnant patients

In 2024 Louisiana enacted a law that placed misoprostol and mifepristone on the controlled-substance schedule, removing them from the portable hemorrhage carts used in obstetric emergencies. Physicians like New Orleans OB-GYN Nicole Freehill warn that the resulting two-minute delay while a nurse retrieves the drug from a secure room can allow a patient to lose a liter of blood, worsening outcomes, especially since alternative medications are contraindicated for conditions such as asthma or high blood pressure and are more expensive.

The reclassification was championed by Republican state Sen. Thomas Pressly after a coerced-abortion incident, and it follows the state's near-total abortion ban, which has not curbed medication abortions that continue via telehealth. Health officials and groups—including the New Orleans Health Department, the Society of Family Planning, and the Guttmacher Institute—report rising hemorrhage rates and pharmacist uncertainty, with some refusing to fill prescriptions.

Related legal challenges to abortion-pill restrictions are pending before the U.S. Supreme Court. Critics argue the law harms patients without reducing abortions.